Extended antitumor responseof a BRAF V600E papillary thyroid carcinoma to vemurafenib

Case Reports in Oncology

Volumn 7, Issue 2, 2014, Pages 343-348

  Ali, Siraj M ^a   He, Je ^a   Carson, Wade ^b   Stephens, Phil J ^a   Fiorillo, Joseph ^b   Lipson, Doron ^a   Palmer, Gary A ^a   Ross, Jeffrey S ^a   Miller, Vincent A ^a   Sharman, Jeffrey ^b  

^a FOUNDATION MEDICINE   (United States)

^b Willamette Valley Cancer Center   (United States)

Author keywords

BRAF V600E; Papillary thyroid carcinoma; Vemurafenib

Indexed keywords

DNA; FLUORINE 18; IODINE 131; THYROGLOBULIN; THYROTROPIN; VEMURAFENIB;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DYSPNEA; ECHOGRAPHY; FATIGUE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE FREQUENCY; GENETIC VARIABILITY; GENOME; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; LUNG NODULE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; NECK DISSECTION; NECK TUMOR; NEXT GENERATION SEQUENCING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE;

EID: 84924048194     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000363377     Document Type: Article

References (14)

1. Mazzaferri EL, Kloos RT: Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-1463
2. McLeod DS, Sawka AM, Cooper DS: Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 2013;381:1046-1057
3. Busaidy NL, Cabanillas ME: Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985
4. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428
5. Xing M, Haugen BR, Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381:1058-1069
6. Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-762
7. Mazzaferri EL: Histologic variants of papillary thyroid carcinoma. Endocr Pract 2001;7:139-142
8. Mazzaferri E: Fine-needle aspiration biopsy, ultrasound and BRAF(v600E) analysis-is this the best FNAB combination for most patients? Clin Endocrinol (Oxf) 2011;75:740-742
9. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, et al: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493-1501
10. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI: Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF mutation. Thyroid 2013;10:1277-1283
11. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031
12. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012;11:873-886
13. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-103
14. Brose MS, Cabanillas ME, Cohen EEW, et al: An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine (abstract LBA28). Presented at the European Cancer Congress 2013, Amsterdam, September 27-October 1, 2013.